DEA Form 225: A Complete Guide for Manufacturers, Researchers, and Laboratories

Federal cannabis regulation changed more in April 2026 than it had in the previous 55 years — and for a growing list of cannabis manufacturers, researchers, and laboratories, the practical consequence is a single federal form. DEA Form 225 is the application that authorizes a business to manufacture, distribute, research, test, import, or export controlled substances under the Controlled Substances Act. As medical marijuana moves to Schedule III and a federal registration pathway opens for state-licensed operators, understanding Form 225 is no longer optional for serious operators. This guide from our team of cannabis compliance and DEA registration consultants covers what the form is, who needs it, what it requires, and where cannabis fits.

What is DEA Form 225?

DEA Form 225 is the New Application for Registration filed with the U.S. Drug Enforcement Administration's Diversion Control Division. It is the entry point to federal authorization for businesses that handle controlled substances in a non-practitioner capacity: manufacturers, distributors, researchers, analytical laboratories, importers, exporters, reverse distributors, and canine handlers. The renewal version of the same form is DEA Form 225a.

Under the Controlled Substances Act (CSA), it is a federal crime to manufacture, distribute, research, or otherwise handle a Schedule I–V controlled substance without an active DEA registration tied to that specific activity. Form 225 is how an organization requests that authorization. Applications are submitted online through the DEA's secure portal; the agency then assigns a Diversion Investigator who reviews the file and, in most cases, inspects the applicant's premises before a Certificate of Registration is issued.

The purpose of the registration

The registration exists to give the federal government visibility and control over the legitimate supply chain for controlled substances — and to prevent diversion into illicit channels. A DEA registration is activity-specific and site-specific: it ties a defined business activity (manufacturing, for example) to a defined physical location and a defined set of drug schedules and codes. Add a location, a new activity, or a new schedule, and you generally need a separate or amended registration.

Who uses DEA Form 225?

Form 225 covers the "business activity" registrant categories — the parts of the supply chain that move, make, study, or test controlled substances rather than prescribe or dispense them to patients. Here is who falls under each category, with notes on where cannabis operators fit.

Manufacturers

Any entity that produces, prepares, propagates, compounds, or processes a controlled substance. In cannabis terms, this includes extractors, processors, and infused-product makers — and, under the new Schedule III pathway, state-licensed medical cannabis manufacturers seeking federal authorization. Manufacturer registration carries the highest fee and the most rigorous security and recordkeeping scrutiny.

Distributors

Entities that deliver, sell, or otherwise distribute controlled substances between registered parties — for example, a wholesaler moving product from a manufacturer to other licensees. Cannabis distributors operating under a state medical license use Form 225 to register federally under § 1301.13(k).

Researchers

Universities, hospitals, contract research organizations, and individual investigators studying controlled substances. Researchers handling Schedule I substances face additional requirements, including a research protocol and, for clinical work, an FDA Investigational New Drug (IND) exemption. Cannabis research has its own evolving framework, covered in detail below.

Analytical laboratories

Labs that analyze controlled substances — including the potency, pesticide, heavy-metal, and microbial testing that every regulated cannabis market requires. An analytical laboratory registration lets a lab legally possess and handle controlled-substance reference standards and samples. For cannabis testing facilities, this is the registration that becomes relevant as marijuana enters the federal scheduling framework.

Importers and exporters

Entities bringing controlled substances into, or sending them out of, the United States. These registrations sit alongside separate import/export permit requirements that remain in force under international treaty obligations, even for Schedule III material.

What activities require DEA registration?

The CSA ties registration to specific, defined activities. You need a DEA registration before you can lawfully:

• Manufacture a controlled substance (including extraction, processing, and compounding)
• Distribute controlled substances to other registrants
• Conduct research with controlled substances
• Operate an analytical laboratory that handles controlled substances
• Import or export controlled substances
• Reverse-distribute (manage returns and destruction of controlled substances)
• Dispense controlled substances to patients (this uses Form 224, not 225)

Two principles govern all of them. First, registration is tied to a single physical location — a multi-site operator generally needs a separate registration, and a separate fee, for each facility. Second, registration is tied to the schedules and drug codes you actually handle; you check those on the application, and handling anything outside them is a violation.

For cannabis, the trigger is the scheduling status of the product. Marijuana handled under a qualifying state medical program is now Schedule III, which brings those activities into the federal registration system. Adult-use (recreational) marijuana and most bulk marijuana outside those channels remain Schedule I as of mid-2026 — so the registration obligation depends on exactly what you handle and under what state authority.

How Form 225 differs from other DEA registrations

The DEA uses different application forms for different registrant categories. Choosing the wrong one delays your application from day one. Here is how the four core forms compare.

Fees also vary sharply by activity. The figures below reflect the current DEA fee schedule under 21 CFR Part 1301:

The practical takeaway for cannabis: a manufacturer or distributor uses Form 225; a dispensary uses Form 224; a testing lab and a research organization use Form 225 at the analytical-lab or researcher fee tier. A vertically integrated operator may need more than one registration, and pays per registration, per site.

Information required during the application

Form 225 collects a standard set of registrant data, plus activity-specific attachments. Expect to provide:

• Applicant identification: legal entity name, any DBA, and a federal tax identification number (or SSN for individual applicants)
• Physical business address: a real street address is required — a P.O. box cannot serve as the primary registered location
• Business activity: you check a single business-activity box (manufacturer, distributor, researcher, analytical lab, importer, or exporter)
• Schedules and drug codes: every schedule and substance code you intend to handle, including whether you bulk-manufacture
• Ownership and background disclosures, plus any prior denial, revocation, or surrender of a DEA registration
• Security provisions: a description of how controlled substances will be stored and safeguarded against diversion, consistent with the physical-security standards in 21 CFR 1301.71–1301.76
• Standard operating procedures (SOPs) covering handling, inventory, recordkeeping, and destruction
• The applicable registration fee

Researchers handling Schedule I substances submit a research protocol, and clinical investigations require an FDA Investigational New Drug (IND) exemption. Applicants entering through the cannabis pathway under § 1301.13(k) attach their state medical marijuana license credentials, which the DEA treats as evidence of state-law authorization.

After you submit, a DEA Diversion Investigator is assigned to your application. The investigator typically issues a pre-registration questionnaire and schedules an on-site inspection to verify your security and storage before the registration is granted.

Common DEA registration challenges

Most registration delays are not caused by the form itself — they are caused by what the form requires you to have ready. The recurring trouble spots:

Physical security and storage

This is the single biggest hurdle. The DEA's physical-security requirements — vaults or safes, alarm systems, access controls, and tightly limited keyholder lists — are specific and inspected in person. Facilities that were built for state-program standards often need upgrades to satisfy federal expectations.

Incomplete SOPs

A missing or thin standard operating procedure can stall an otherwise strong application. The DEA wants to see documented, workable procedures for inventory, recordkeeping, handling, and destruction — not aspirational placeholders.

Ownership and background complexity

Layered ownership structures, out-of-state principals, and prior regulatory history all require careful disclosure. Gaps or inconsistencies here trigger questions that extend the review.

The site-specific, multi-registration reality

Operators frequently underestimate that each location and each distinct activity needs its own registration and fee. Budgeting and sequencing these correctly avoids surprises.

DEA registration and cannabis research

For roughly five decades, cannabis researchers in the United States had a single legal source of research-grade marijuana: one DEA-registered cultivator at the University of Mississippi, supplying the National Institute on Drug Abuse (NIDA). The material was widely criticized as low-potency and unrepresentative of what patients actually use, and the registration process for Schedule I research was slow and security-heavy.

Two changes loosened that bottleneck. In December 2020, the DEA finalized a rule to register additional bulk marijuana manufacturers, and by 2022 several new manufacturers had been registered. Then, on December 2, 2022, Congress enacted the Medical Marijuana and Cannabidiol Research Expansion Act — the first standalone cannabis bill to clear both chambers in decades. It established a streamlined, separate registration process for marijuana research, directed the DEA to register both researchers and manufacturers who supply them, and imposed response deadlines on the agency (an initial decision or request for more information within 60 days).

The April 2026 Final Order went further. Researchers registered to study marijuana under 21 CFR § 1301.13 can now source marijuana directly from a state medical licensee that holds a valid federal § 1301.13(k) registration — with an explicit liability shield and non-retaliation language written into the rule. In practice, NIDA's supply program continues to exist, but it is now one option among many rather than the only door.

For universities, hospitals, and research organizations, the mechanics still run through Form 225 at the researcher fee tier, the registration remains site-specific, and clinical work still routes through the FDA's IND process. What has changed is access — both to material and to a registration system that is, for the first time in a generation, designed to say yes to qualified applicants.

How Cannaspire helps you navigate DEA registration

DEA registration sits at the intersection of regulatory compliance, facility design, and operational documentation — the exact disciplines Cannaspire was built on. As a national cannabis consulting firm, we help manufacturers, distributors, analytical laboratories, research organizations, and pharmaceutical cannabis operators move from "we think we need to register" to an approved Certificate of Registration. Our cultivation and manufacturing specialists, Warren and Beck, bring hands-on facility and process expertise to the security and SOP work that determines whether an application clears.

Engagements typically include:

• Registration scoping — confirming the correct form, fee tier, schedules, and number of registrations for your activities and sites
• Facility and security review — auditing storage, access controls, and alarms against federal physical-security standards before an inspector ever arrives
• SOP and documentation development — building the inventory, recordkeeping, handling, and destruction procedures the DEA expects to see
• Application preparation and the § 1301.13(k) cannabis filing, including assembling state credentials and supporting attachments
• GMP readiness for manufacturers pursuing pharmaceutical-grade production — see our GMP consulting services
• Ongoing compliance after registration, including renewals on Form 225a

If your work is dispensary-side, our guidance on DEA registration for dispensaries and medical marijuana DEA registration walks through the Form 224 pathway and what the Schedule III change means for retail medical operators.

Preparing for what comes next

The April 2026 order was explicitly framed as a first step, not the finish line. The DEA opened a separate administrative hearing on June 29, 2026 to consider rescheduling marijuana more broadly — potentially extending Schedule III status beyond medical to adult-use cannabis. That outcome is not guaranteed, and any further rule could take months after the hearing concludes. Until then, a dual federal framework applies: medical marijuana under qualifying state programs is Schedule III, while adult-use and most bulk marijuana remain Schedule I.

What that means for operators is simple. The organizations that understand DEA registration now — which form applies, what the security and documentation bar looks like, how the § 1301.13(k) pathway works — are the ones positioned to act quickly as the framework expands. Manufacturers, researchers, and laboratories that treat federal registration as a capability to build rather than a problem to react to will have a real head start.

Whether you are filing today or preparing for a wider opening, getting the registration right the first time protects your operations and your timeline. That is the work we do.

Frequently asked questions

Disclaimer: This guide reflects federal cannabis and DEA registration developments through June 2026, including the April 2026 Department of Justice Final Order rescheduling FDA-approved marijuana products and state-licensed medical marijuana to Schedule III and establishing the expedited registration pathway at 21 CFR § 1301.13(k). Fees, deadlines, and procedures are set by DEA regulation and may change. This content is for informational purposes only and does not constitute legal advice. Consult qualified counsel and licensed consultants before making registration or business decisions. Last updated: June 2026.